drugset
drugset / Trial / NCT04541368

A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy

NCT04541368 ↗

Phase 0 Not yet recruiting 50 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

Clinical trial for the safety and efficacy of CS1-targeted CAR-T Cells therapy for relapsed multiple myeloma after BCMA CAR-T cells therapy

Timeline

Start
2020-12-31
Primary completion
2023-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CS1 Targeted CAR T-cells Cell therapy — Intravenous

Indications

No indication recorded.